Considerations for the Identification and Management of Geographic Atrophy: Recommendations from an Expert Panel

Newly approved treatments for patients with geographic atrophy are changing the treatment paradigm, highlighting the need for eye care providers (ECPs) to have a set of recommendations on how to best manage GA patients. Here, we outline how to identify various stages of age-related macular degenerat...

Full description

Saved in:
Bibliographic Details
Published inClinical ophthalmology (Auckland, N.Z.) Vol. 18; pp. 325 - 335
Main Authors Regillo, Carl D, Nijm, Lisa M, Shechtman, Diana L, Kaiser, Peter K, Karpecki, Paul M, Ryan, Edwin H, Ip, Michael S, Yeu, Elizabeth, Kim, Terry, Rafieetary, Mohammad R, Donnenfeld, Eric D
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2024
Dove
Dove Medical Press
Subjects
age-related macular degeneration
Care and treatment
Expert Opinion
Macular degeneration
Oral contraceptives
patient care
Patient compliance
Pharmaceutical industry
retina
treatment
Switzerland
treatment
patient care
retina
age-related macular degeneration
Online AccessGet full text

Cover

More Information
Summary:Newly approved treatments for patients with geographic atrophy are changing the treatment paradigm, highlighting the need for eye care providers (ECPs) to have a set of recommendations on how to best manage GA patients. Here, we outline how to identify various stages of age-related macular degeneration including geographic atrophy (GA) by examining optimal management scenarios implicating various ECPs and reviewing treatment considerations for patients with GA. Early identification of GA will lead to optimal patient outcomes, while a standardized management scenario will reduce clinical burden among ECPs treating patients with GA.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1177-5467
1177-5483
1177-5483
DOI:10.2147/OPTH.S445755